DRUG REGULATORY AUTHORITY OF PAKISTAN
Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: Nº I/S/09-25-74

CRACKDOWN AGAINST FALSIFIED / SPURIOUS PRODUCTS

Date: **19th September , 2025**

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- General Public

Problem Statement:

Provincial Drug Testing Laboratories have informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared ***'Spurious'***. The details of reports are as under:

S#	Product Name	Batch No.	Purported Manufacturer	Remarks
1.	Efaston tablet (Dydrogesterone 10mg)	41160	Purported to be manufactured by Lahore Chemical & Pharmaceutical Works (Pvt.) Ltd., Lahore.	Spurious (Does not contain active ingredient)
2.	Paracare 60ml suspension (Paracetamol 120mg/5ml)	PE-042	Purported to be manufactured by Wellcare Pharmaceuticals, Sargodha.	Spurious (Does not contain active ingredient)

Risk Statement:

All the above mentioned purported drug products are confirmed as **falsified/spurious,** as the laboratory testing has revealed that the product contains **no active pharmaceutical ingredient**, resulting in **complete lack of therapeutic effect**. Such falsification poses a **serious risk to public health**, potentially leading to **treatment failure**, **disease progression**, and even **life-threatening outcomes**, particularly for patients relying on these medications for critical care. The public is strongly advised **not to use these purported drug products** and to report any suspicious or unverified medicines to DRAP immediately.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

DRAP, Islamabad + 92 051 9255969 gsms@dra.gov.pk

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج

DRAP, Islamabad | + 92 051 9255969 | gsms@dra.gov.pk